A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY OF SECUKINUMAB TO COMPARE 300 MG AND 150 MG AT WEEK 52 IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO ARE RANDOMIZED TO DOSE ESCALATION AFTER NOT ACHIEVING INACTIVE DISEASE DURING AN INITIAL
Principal Investigator(s)
Escalante, Agustin
Funded by
NOVARTIS PHARMACEUTICALS CORPORATION
Research Start Date
Status
Active